Teladoc Health Reports Second-Quarter 2021 Results, Raises Full-Year Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P dip, trading choppy as tech stocks fall
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
Teladoc (TDOC) Falls 6% on Growing Losses and Weak Guidance to Prompt a Downgrade to 'Hold' at Deutsche Bank
July 28, 2021 10:01 AM EDTShares of Teladoc Health (NYSE: TDOC) are down more than 6% in todays trading session after the company presented disappointing Q2 results.
The company reported a loss of $0.86 per share while the surveyed analysts were expecting a loss of just $0.53 per share. Losses have more than doubled compared to $0.34 a year ago. Revenue grew 109% year-over-year to $503 million.
Teladoc Health delivered a strong second quarter, marked by exciting new client wins, product launches, and tremendous progress on our quest to be the category-defining provider of whole person virtual care, said Jason Gorevic, chief executive... More
Teladoc (TDOC) PT Lowered to $185 at Cantor Fitzgerald
July 28, 2021 6:46 AM EDTCantor Fitzgerald analyst Steven Halper lowered the price target on Teladoc (NYSE: TDOC) to $185.00 (from $210.00) while maintaining a Neutral rating.
The analyst commented, "We reiterate our Neutral rating on TDOC shares and lower our price target to $185 from $210. After the market close on Tuesday, July 27, TDOC reported 2Q21 results. Revenue and... More
Teladoc (TDOC) Q2 Revenue Tops Consensus, Offers Guidance
July 27, 2021 4:13 PM EDTTeladoc (NYSE: TDOC) reported Q2 EPS of ($0.86), may not compare to the analyst estimate of ($0.56). Revenue for the quarter came in at $503 million versus the consensus estimate of $500.7 million.
GUIDANCE:
Teladoc sees Q3 2021 EPS of ($0.78)-($0.68), versus the consensus of... More
